Bausch Health Companies Inc. Defined Benefit Plan, Effect of One Percentage Point Decrease on Accumulated Postretirement Benefit Obligation
Bausch Health Companies Inc. (BHC) reported Defined Benefit Plan, Effect of One Percentage Point Decrease on Accumulated Postretirement Benefit Obligation of $600.00 thousand for the 12-month period ending 2015-12-31, per its 10-K filed 2016-04-29.
Discontinued › Notes › Compensation Related Costs › Defined Benefit Plan › Defined Benefit Plan, Effect of One-Percentage-Point Change in Assumed Health Care Cost Trend Rate
us-gaap:DefinedBenefitPlanEffectOfOnePercentagePointDecreaseOnAccumulatedPostretirementBenefitObligation1 · last filed 2016-04-29
- Bausch Health Companies Inc. defined benefit plan, effect of one percentage point decrease on accumulated postretirement benefit obligation for fiscal 2015 was $600.00K, a 33.33% decline from fiscal 2014.
- Bausch Health Companies Inc. defined benefit plan, effect of one percentage point decrease on accumulated postretirement benefit obligation for fiscal 2014 was $900.00K, a 3.54% decline from fiscal 2013.
- Bausch Health Companies Inc. defined benefit plan, effect of one percentage point decrease on accumulated postretirement benefit obligation for fiscal 2013 was $933.00K.
| Period end | Defined Benefit Plan, Effect of One Percentage Point Decrease on Accumulated Postretirement Benefit Obligation 12 month |
|---|---|
| 2015-12-31 | $600.00K 10-K · filed 2016-04-29 |
| 2014-12-31 | $900.00K 10-K · filed 2015-02-25 |
| 2013-12-31 | $933.00K 10-K · filed 2014-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 |